TY  - GEN
AU  - Campos Mena, Sandra
AU  - Pérez-Gimeno, Gloria
AU  - Lorusso, Nicola
AU  - Álvarez Río, Virginia
AU  - Basile, Luca
AU  - Batalla Rebollo, Noa
AU  - García-Comas, Luis
AU  - Andreu Ivorra, Blanca
AU  - Pérez-Panadés, Jordi
AU  - Ramos Marín, Violeta
AU  - Castrillejo, Daniel
AU  - Fernández Ibáñez, Ana
AU  - Rafael de la Cruz López, María Ángeles
AU  - Nuñez, Olivier
AU  - Monge Corella, Susana
AU  - Grupo SiVIRA de vigilancia y efectividad vacunal en España
PY  - 2025
DO  - 10.1017/S0950268825100782
UR  - https://hdl.handle.net/20.500.12105/27328
AB  - Effectiveness of nirsevimab against respiratory syncytial virus (RSV) hospitalization during the 2024/2025 season in Spain was estimated using a test-negative design (TND) and hospital-based respiratory infections surveillance data. Children born...
LA  - eng
PB  - Cambridge University Press
KW  - Immunization
KW  - Infant
KW  - Nirsevimab
KW  - Respiratory syncytial virus
KW  - Surveillance system
KW  - Test-negative design
KW  - Antibodies, Monoclonal, Humanized
KW  - Antiviral Agents
KW  - Case-Control Studies
KW  - Child, Preschool
KW  - Female
KW  - Hospitalization
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Male
KW  - Respiratory Syncytial Virus Infections
KW  - Respiratory Syncytial Virus, Human
KW  - Spain
TI  - Monitoring effectiveness of nirsevimab immunization against RSV hospitalization using surveillance data: a test-negative case-control study, Spain, October 2024-March 2025.
TY  - research article
ER  -